Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0589 • ACR Convergence 2022
Restoration of NAD+ Levels in Rheumatoid Arthritis with NAD+ Boosters as a Novel Therapeutic Strategy to Resolve Acute Inflammation
Carlos Pérez-Sánchez¹, Adrián Llamas Urbano², Tomás Cerdó², Laura Muñoz-Barrera¹, Ismael Sánchez-Pareja², Luz Marina Sánchez-Mendoza³, Nuria Barbarroja¹, María Carmen Ábalos-Aguilera⁴, Juan Antonio Moreno⁵, María isabel Burón⁶, José Antonio González-Reyes⁵, Pilar Font¹, Jerusalem Calvo-Gutierrez², Marta Rojas-Gimenez¹, Eduardo Collantes¹, Alejandro Escudero-Contreras², José Manuel Villalba-Montoro⁶ and Chary Lopez-Pedrera¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ³Department of Cell Biology, Physiology and Immunology, University of Córdoba, Campus de Excelencia Internacional Agroalimentario, ceiA3, Cordoba, Spain, Córdoba, Spain, ⁴Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, ⁵Department of Cell Biology, Physiology and Immunology, University of Córdoba, Campus de Excelencia Internacional Agroalimentario, ceiA3, Córdoba, Spain, ⁶Department of Cell Biology, Physiology and Immunology, University of Córdoba, Campus de Excelencia Internacional Agroalimentario, ceiA3, Cordoba, Spain
Background/Purpose: This study aimed to: 1- Evaluate the levels of NAD+ and gene transcripts involved in its metabolism in Rheumatoid Arthritis (RA) patients. 2- Analyse…
Abstract Number: 0605 • ACR Convergence 2022
Citrullinated Peptide-Specific ACPA Are Present in the Female Genital Tract in Premenopausal Women with and Without RA
Daniele Marcy¹, Heather Rothfuss², Ashley Visser¹, Jill Norris³, V. Michael Holers⁴, Kevin D Deane⁵, William Robinson⁶, Brian Cherrington² and Kristen Demoruelle¹, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Wyoming, Laramie, ³Colorado School of Public Health, Aurora, CO, ⁴University of Colorado, Denver, CO, ⁵University of Colorado Denver Anschutz Medical Campus, Denver, CO, ⁶Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Women develop RA ~3 times more often than men. The etiology of this sex difference remains largely unexplained. Generation of anti-citrullinated protein antibodies (ACPA)…
Abstract Number: 0623 • ACR Convergence 2022
Rheumatoid Synovial Fibroblasts Display Imprinted Memory of Their Synovial Endotype Which Can Be Plastically Modulated by B-cells Crosstalk
Edoardo Prediletto¹, Cankut Cubuk², Elena Pontarini³, Felice Rivellese², Alessandra Nerviani², Davide Lucchesi³, Mattia Caliste¹, Elisa Corsiero¹, Manzoor Ahmed³, rebecca hands³, Myles Lewis², Costantino Pitzalis² and Michele Bombardieri⁴, ¹Wlliam Harvey Research Institute Queen Mary University on London, London, United Kingdom, ²Queen Mary University of London, London, United Kingdom, ³William Harvey Research Institute, London, United Kingdom, ⁴Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom
Background/Purpose: Despite advances in the treatment of Rheumatoid Arthritis (RA), synthetics and biologicals drugs are ineffective in ~40% of patients. The origin of this refractoriness…
Abstract Number: 0751 • ACR Convergence 2022
Accessing Telehealth and In-Person Healthcare During the COVID-19 Pandemic: Experiences of Individuals with Rheumatoid Arthritis
Smruthi Ramachandran¹, Jenny Leese², Stephanie Therrien³, Catherine L. Backman¹, Jasmin Ma⁴, Kelly English⁵, Eileen Davidson⁶, Shanon McQuitty⁷, Alison Hoens⁵, Cheryl Koehn⁸, James Gavin⁹, jo Adams⁹ and Linda Li¹, ¹University of British Columbia, Vancouver, BC, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Arthritis Research Canada/University of British Columbia, Richmond, BC, Canada, ⁵Arthritis Patient Advisory Board of Arthritis Research Canada, Vancouver, BC, Canada, ⁶Arthritis Patient Advisory Board of Arthritis Research Canada, Burnaby, BC, Canada, ⁷Arthritis Patient Advisory Board of Arthritis Research Canada, Richmond, BC, Canada, ⁸Arthritis Consumer Experts, Vancouver, BC, Canada, ⁹University of Southampton, Southampton, United Kingdom
Background/Purpose: The COVID-19 pandemic has provided opportunity to increase integration of virtual healthcare with in-person medical practices. Individuals with rheumatoid arthritis (RA) continue to self-manage…
Abstract Number: 0807 • ACR Convergence 2022
High Throughput Analyses for the Study of Synovial Tissue Biopsy from Inflammatory Arthritis Patients
Viviana Marzaioli¹, Achilleas Floudas², Aine Gorman³, Carl Orr⁴, Douglas Veale⁵ and Ursula Fearon⁶, ¹Trinity College Dublin and University College Dublin, Dublin, Ireland, ²Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Ireland, ³St Vincent's University Hospital, Dublin, Ireland, ⁴Saint Vincent's University Hospital, Dublin, Ireland, ⁵St. Vincent's University Hospital, Blackrock, Dublin, Ireland, ⁶Trinity College Dublin, Dublin, Ireland
Background/Purpose: Inflammatory arthritis (IA) is a chronic systemic autoimmune disease of unknown aetiology, which affects the joints. While studies of immune cell populations in peripheral…
Abstract Number: 0895 • ACR Convergence 2022
COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Rheumatoid Arthritis
Naveen R¹, Ioannis Parodis², Mrudula Joshi³, Parikshit Sen⁴, Minchul Kim⁵, Vishwesh Agarwal⁶, Sinan Kardes⁷, James B. Lilleker⁸, Hector Chinoy⁹, Oliver Distler¹⁰, Ai Lyn Tan¹¹, Samuel Shinjo¹², Babur Salim¹³, Tamer A Gheita¹⁴, Nelly Ziade¹⁵, Tsvetelina Velikova¹⁶, Tulika Chatterjee⁵, Arvind Nune¹⁷, Marcin Milchert¹⁸, Abraham Edgar Gracia-Ramos¹⁹, Albert Selva O’Callaghan²⁰, Miguel Angel Saavedra Salinas²¹, Lorenzo Cavagna²², Masataka Kuwana²³, Johannes Knitza²⁴, Jessica Day²⁵, Ashima Makol²⁶, John Pauling²⁷, Chris Wincup²⁸, Erick Zamora Tehozol²⁹, Jorge Rojas Serrano³⁰, Ignacio Garcia-De La Torre³¹, Rohit Aggarwal³², Vikas Agarwal¹, Latika Gupta³³, Elena Nikiphorou³⁴ and CoVAD Study Group³⁵, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Karolinska Institutet, Stockholm, Sweden, ³Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ⁴Maulana Azad Medical College, New Delhi, India, ⁵University of Illinois College of Medicine Peoria, Peoria, IL, ⁶Mahatma Gandhi Missions Medical College, Lucknow, India, ⁷Istanbul University, Istanbul, Turkey, ⁸The University of Manchester, Manchester, United Kingdom, ⁹The University of Manchester, Sale, United Kingdom, ¹⁰Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ¹¹University of Leeds, Leeds, United Kingdom, ¹²Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, ¹³Fauji foundation hospital Rawalpindi, Rawalpindi, Pakistan, ¹⁴Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹⁵Saint-Joseph University, Beirut, Lebanon, ¹⁶Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹⁷Southport and Ormskirk Hospital NHS Trust, Southport, United Kingdom, ¹⁸Pomeranian Medical University in Szczecin, Szczecin, Poland, ¹⁹Instituto Mexicano del Seguro Social, Ciudad de México, Mexico, ²⁰Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²¹IMSS, Ciudad de México, Mexico, ²²Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy, ²³Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²⁴Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²⁵Walter and Eliza Hall Institute, Melbourne, Australia, ²⁶Mayo Clinic, Rochester, MN, Rochester, MN, ²⁷North Bristol NHS Trust, Bristol, United Kingdom, ²⁸Rayne Institute, University College London, London, United Kingdom, ²⁹Centro Medico Pensiones, Merida, Mexico, ³⁰Hospital Angeles Villahermosa, Ciudad de México, Mexico, ³¹Centro de Est. de Inv. Bas. y Clinica, S.C., Guadalajara, Mexico, ³²Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ³³Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom, ³⁴Leiden University Medical Center & King's College London, London, United Kingdom, ³⁵CoVAD study group, Wolwehampton, United Kingdom
Background/Purpose: COVID-19 vaccination in autoimmune diseases (COVAD) study is a large-scale real-world data on COVID-19 vaccine safety in autoimmune rheumatic diseases (AIRDs) including rheumatoid arthritis…
Abstract Number: 0911 • ACR Convergence 2022
Peer Coach Intervention to Improve Primary Cardiovascular Disease Screening for Patients with Rheumatoid Arthritis
Iris Navarro-Millan¹, Mackenzie Brown², Yuliana Domínguez Páez³, Geyanne Lui⁴, Joan Weiner¹, Shelley fritz¹, Tien Sydnor-Campbell⁵, Aberdeen Allen⁶, Assem Jabri¹, Shilpa Venkatachalam⁷, Kelly Gavigan⁸, William Benjamin Nowell⁹, Jeffrey Curtis¹⁰, Liana Fraenkel¹¹ and Monika Safford¹, ¹Weill Cornell Medicine, New York, NY, ²Weill Cornell Medicine, Brooklyn, NY, ³Weill Cornell Medicine, Bronx, NY, ⁴Albert Einstein College of Medicine, New York, NY, ⁵Weill Cornell Medicine, Philedelphia, ⁶Weill Cornell Medicine, Parlin, ⁷Global Healthy Living Foundation, New York, NY, ⁸Global Healthy Living Foundation, Upper Nyack, NY, ⁹Global Healthy Living Foundation, Nyack, NY, ¹⁰University of Alabama at Birmingham, Hoover, AL, ¹¹Berkshire Medical Center, Lenox, MA
Background/Purpose: Only 37% of patients with rheumatoid arthritis (RA) receive screening for cardiovascular disease (CVD) despite their high risk. To improve CVD prevention, we designed…
Abstract Number: 0927 • ACR Convergence 2022
Review of 167,990 Same Day RAPID3, CDAI Scores for 61,312 Patients Receiving DMARD Treatment for Rheumatoid Arthritis; Evaluations of Disease Assessments and Treatment Discontinuation
Nehad Soloman¹, Kent Kwas Huston², Jasvinder singh³, Simon Helfgott⁴, Andrew Frick⁵, Scott Milligan⁵ and Colin Edgerton⁶, ¹Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ²Kansas City Physician Partners Center for Rheumatic Disease, Kansas City, MO, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Trio Health, Louisville, CO, ⁶Articularis Healthcare, Sullivans Island, SC
Background/Purpose: Treatment efficacy for rheumatoid arthritis is often measured through disease assessments containing subjective input from the provider, the patient, or both. Here we compare…
Abstract Number: 1094 • ACR Convergence 2022
Mechanical Loading-induced BHLHE40 Promotes Inflammatory Arthritis
Eric Gracey¹, Carolien Vlieghe², Isabelle Cambre¹, Elisabeth Gilis¹, Flore Stappers³, Guillaume Planckaert¹, Rik Lories⁴, Aline Bozec⁵ and Dirk Elewaut⁶, ¹Ghent University, Gent, Belgium, ²VIB-UGent Center for Inflammation Research, Ghent University, Belgium, Gent, Belgium, ³VIB-UGent Center for Inflammation Research, Ghent University, Ghent, Belgium, ⁴KU Leuven, Leuven, Belgium, ⁵Universitätsklinikum Erlangen, Erlangen, Germany, ⁶Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium
Background/Purpose: Force induced microdamage to joint tissue is hypothesized to trigger inflammatory events in the joint leading to arthritis. Patients with inflammatory arthritis, such as…
Abstract Number: 1210 • ACR Convergence 2022
Use of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs and the Risk of Lymphoma in Rheumatoid Arthritis
Namrata Singh¹, Alexander Peterson², Aaron Baraff², Ajay Gopal³, Nicholas Smith⁴, Jennifer Barton⁵, Jeffrey Curtis⁶ and Noel Weiss³, ¹University of Washington, Bellevue, WA, ²VA Puget Sound, SEATTLE, WA, ³University of Washington, Seattle, WA, ⁴VA Puget Sound/University of Washington, Seattle, WA, ⁵VA Portland Health Care System/OHSU, Portland, OR, ⁶University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Epidemiologic studies suggest that disease duration and degree of inflammatory activity of rheumatoid arthritis (RA) are associated with lymphoma development [1]. Whether the decrease…
Abstract Number: 1333 • ACR Convergence 2022
Patient Perceptions of Rheumatoid Arthritis Blood Work: A Cross-sectional Survey in the ArthritisPower Registry
William Nowell¹, Shilpa Venkatachalam², Kelly Gavigan¹, Michael George³, Johanna Withers⁴, Laura Stradford⁵, Esteban Rivera¹ and Jeffrey Curtis⁶, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Global Healthy Living Foundation, New York, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Scipher Medicine Corportaion, Waltham, MA, ⁵Global Healthy Living Foundation, Nyack, NY, ⁶Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Although patients' (pts) perspective on disease-related lab testing and its role in treatment decision-making has been examined for some chronic illnesses, ranging from diabetes…
Abstract Number: 1395 • ACR Convergence 2022
Comparative Safety of Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Patients Undergoing Treatment for Rheumatoid Arthritis
Yao-Fan Fang¹ and Lai-Chu See², ¹Chang Gung Memorial Hospital, Taoyuan, Taiwan, ²Biostatistics Core Laboratory, Molecular Medicine Research centre, Chang Gung University, Taoyuan, Taiwan
Background/Purpose: Since 2010, biological disease-modifying antirheumatic drugs (bDMARDs) have been the dominant mode of treatment for rheumatoid arthritis (RA). However, the safety of DMARDs, such…
Abstract Number: 1411 • ACR Convergence 2022
Predictors of Achieving Clinical Remission in ACPA-positive RA-patients Treated with Abatacept and Methotrexate or Methotrexate Monotherapy
Marloes Verstappen¹, Ellis Niemantsverdriet², Tom Huizinga¹, Annette van der Helm-van Mil³ and Sytske Anne Bergstra², ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands, ³Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: With a wide range of disease modifying treatment available, clinical remission is frequently achieved in rheumatoid arthritis (RA). Although a proportion of RA-patients achieves…
Abstract Number: 1430 • ACR Convergence 2022
Time to First Remission and Prevalence of Sustained Remission After Etanercept Biosimilar (ETA-B) or Originator (ETA-O) Initiation in Rheumatoid Arthritis
Cristiano Moura¹, Luck Lukusa¹, Laura Yan¹, Walter P Maksymowych², Denis Choquette³, Gilles Boire⁴ and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: The first biosimilar etanercept (ETA-B) was approved in Canada in 2016, but real-world data comparing the effectiveness of ETA-B versus its equivalent originator (ETA-O)…
Abstract Number: 1605 • ACR Convergence 2022
Profound Anticoagulant Effects of Initial Antirheumatic Treatments in Early Rheumatoid Arthritis Patients; A NORD-STAR Spin-off Study
Bas Dijkshoorn¹, Daisy Vedder¹, Anna Rudin², Dan Nordstrom³, Bjorn Gudbjornsson⁴, Kristina Lend⁵, Till Uhlig⁶, Espen Haavardsholm⁶, Gerdur Maria Grondal⁷, Merete L Hetland⁸, Marte Heiberg⁶, Mikkel Østergaard⁹, Kim Horslev-Petersen¹⁰, Jon Lampa¹¹, Ronald van Vollenhoven¹², Aleksandra antovic¹³ and Michael Nurmohamed¹⁴, ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ³Helsinki University Hospital, Helsinki, Finland, ⁴Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁵The Karolinska Institute, Stockholm, Sweden, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷Landspitali University Hospital, Centre for Rheumatology Research, Reykjavik, Iceland, ⁸Rigshospitalet, Glostrup, Denmark, ⁹Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ¹⁰Danish Hospital for Rheumatic Diseases, Haderslev, Denmark, ¹¹Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institutet, Stockholm, Sweden; Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ¹²Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹³Karolinska Institute, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ¹⁴Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk of venous thromboembolism. Thus far, there have not been any comparative studies investigating the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].